FDA Issues Warning Letter to Novo Nordisk Over Unreported Semaglutide Deaths and Systematic Pharmacovigilance Failures
The FDA cited Novo Nordisk for serious violations of adverse event reporting requirements after a 2025 inspection found the company failed to report three patient deaths linked to semaglutide, including one suicide, and lacked adequate procedures for post-marketing drug safety surveillance.
4 min read4 sources